Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 5/20 | 0.54 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263113 | 0.92 | DRD4 (0.50) | UBE2MDCUN1D1SIGMAR1KMT2AMEN1 | |
| SCHEMBL14263134 | 0.86 | DRD4 (0.55) | KMT2AMEN1MCHR1EPHX2DRD4 | |
| SCHEMBL4979582 | 0.86 | SLC6A5 (0.59) | KCNH2MCHR1EPHX2TEAD1DRD4 | |
| SCHEMBL4981951 | 0.85 | MCHR1 (0.56) | UBE2MDCUN1D1SIGMAR1KMT2AKCNH2 | |
| SCHEMBL14263087 | 0.84 | MCHR1 (0.52) | KCNH2MCHR1EPHX2CARM1PRMT6 | |
| SCHEMBL4982704 | 0.84 | CARM1 (0.55) | MCHR1EPHX2CARM1PRMT6DRD4 | |
| SCHEMBL14263126 | 0.83 | SSTR1 (0.57) | UBE2MDCUN1D1KMT2AMEN1MCHR1 | |
| SCHEMBL30229605 | 0.82 | MLYCD (0.51) | KMT2AMEN1P2RX7 | |
| SCHEMBL4981612 | 0.82 | DRD4 (0.57) | UBE2MDCUN1D1SIGMAR1MCHR1EPHX2 | |
| SCHEMBL14263114 | 0.81 | DRD4 (0.73) | KMT2AMEN1MCHR1EPHX2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | UBE2M 4680/4885DCUN1D1 1682/4885SIGMAR1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.